List view / Grid view
Cannabinoids, their potential therapeutic uses and the research needed for medical cannabis were the topics of discussion at the ‘Medical cannabis: what UK doctors need to know’ event held last week.
The CQC decision marks the first time the agency has accepted a clinic to prescribe patients with medical cannabis in the UK.
An import of medicinal cannabis from Portugal to Germany signifies the largest quantity ever moved within the EU, highlighting a surge in the medicinal cannabis products market.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this second piece, we discuss the challenges, legal implications and perceptions of cannabinoids.
This series investigates the growing interest from the pharmaceutical industry in cannabinoids. In this first piece, we hear from industry experts about the current situation of the ingredient on the pharmaceutical market.
The first platform to facilitate the licensed importation of medical cannabis into Europe has formally launched in the UK.
A report has suggested that growth of medical cannabis will reach between $11.9 and $17.1 billion by 2020, and is currently around $5 to $6 billion...
Chromatographic purification of natural compounds presents many challenges to scientists because of the complex nature of the starting matrices that are used in the process...
Peak Scientific, a global leader in gas generation for analytical laboratories, has recently partnered with Ontario-based Molecular Science Corp. (MSC) to supply nitrogen gas generation systems on their first mobile laboratory aimed at the rapidly expanding cannabis testing and research sector...
The FDA has approved Epidiolex oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy...
Researchers demonstrate hemp's ability to slow cancer growth and uncover mechanism for its cancer-fighting ability...
GB Sciences, Inc. is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies...
A study has confirmed that cannabinoids are just as suitable as a prophylaxis for migraine attacks as other pharmaceutical treatments.
